Peritoneal recurrence of thymoma treated by surgery and hyperthermic intraperitoneal chemotherapy

Camille Mazza; Jordi Remon; Charles Honoré; Benjamin Besse

doi:10.1016/j.lungcan.2017.06.011

Peritoneal recurrence of thymoma treated by surgery and hyperthermic intraperitoneal chemotherapy

Lung Cancer. 2017 Sep:111:59-60. doi: 10.1016/j.lungcan.2017.06.011. Epub 2017 Jul 8.

Authors

Camille Mazza¹, Jordi Remon¹, Charles Honoré², Benjamin Besse³

Affiliations

¹ Department of Cancer Medicine, Gustave Roussy, Cancer Campus, Villejuif, France.
² Department of Surgical Oncology, Gustave Roussy, Cancer Campus, Villejuif, France.
³ Department of Cancer Medicine, Gustave Roussy, Cancer Campus, Villejuif, France; Paris-Sud University, Orsay, France. Electronic address: [email protected].

PMID: 28838398
DOI: 10.1016/j.lungcan.2017.06.011

Abstract

Thymomas are rare (1,5 cases/million) and typically occur in adults with a median age of 50 years old. Thymomas are indolent with a 10-year overall survival for resected stage II thymomas of 70%. Late relapses occur in 20% of the cases, and distant metastasis from thymoma is rare. Peritoneal recurrence of thymoma treated with surgery associated with hyperthermic intraperitoneal chemotherapy (HIPEC) has not been described in the literature. This report manages peritoneal recurrence of thymoma with HIPEC, suggesting that aggressive therapies may decrease the risk of recurrence.

Keywords: Hyperthermic intraperitoneal chemotherapy (HIPEC); Peritoneal recurrence; Thymoma.

Publication types

Case Reports

MeSH terms

Combined Modality Therapy
Humans
Hyperthermia, Induced
Male
Middle Aged
Neoplasm Recurrence, Local
Peritoneal Neoplasms / diagnosis
Peritoneal Neoplasms / secondary*
Peritoneal Neoplasms / therapy*
Positron Emission Tomography Computed Tomography
Thymoma / diagnosis
Thymoma / pathology*
Thymoma / therapy
Treatment Outcome